Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Welcome to APCCC 2021
Prof Silke Gillessen and Prof Aurelius Omlin
Welcome to APCCC 2021 ( Prof Silke Gillessen and Prof Aurelius Omlin )
23 Sep 2021
ESMO 2021 Roundup
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
22 Sep 2021
Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal...
Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India
Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma ( Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India )
21 Sep 2021
Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) w...
Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China
Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) with Capecitabine for patients with LARC ( Dr Pei-Rong Ding - Sun Yat-sen University Cancer Center, Guangzhou, China )
20 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
19 Sep 2021
KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-ne...
Prof Hope Rugo - University of California San Francisco, San Francisco, USA
KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )
19 Sep 2021
Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trast...
Prof Nadia Harbeck - University of Munich, Munich, Germany
Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC ( Prof Nadia Harbeck - University of Munich, Munich, Germany )
18 Sep 2021
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advan...
Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer ( Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands )
18 Sep 2021
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone recept...
Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )
18 Sep 2021
Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical ...
Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA
Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer ( Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA )
18 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
18 Sep 2021
6 months trastuzumab non-inferior to 12 months for HER2 positive early breast ca...
Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom
6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer ( Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom )
17 Sep 2021